Skip to main content

Table 1 Demographic and baseline characteristics of the groups of treatment.

From: Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study

Variables

AB sequence N = 8

BA sequence N = 8

Total N = 16

Age (years)

27 ± 4 (24 - 35)

28 ± 5 (21 - 35)

27 ± 4 (21 - 35)

Weight (Kg)

70 ± 11 (60 - 92)

77 ± 12 (58 - 94)

74 ± 12 (58 - 94)

Height (cm)

175 ± 8 (164 - 185)

178 ± 8 (165 - 192)

176 ± 8 (164 - 192)

Body Mass Index

22.9 ± 2.7 (19.0 - 28.4)

24.2 ± 2.6 (20.9 - 29.3)

23.6 ± 2.6 (19.0 - 29.3)

Body surface (m2)

1.84 ± 0.29 (1.58 - 2.42)

2.03 ± 0.32 (1.53 - 2.48)

1.94 ± 0.31 (1.53 - 2.48)

Skin color

   

White

6 (75%)

7 (87.5%)

13 (81.3%)

Non-white

2 (25%)

1 (12.5%)

3 (18.7%)

  1. Data are reported as mean ± standard deviation (range) or number of patients (%).